PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-5.46%
Cash & equivalents declining -5.46% while Medical - Pharmaceuticals shows -2.80% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-5.46%
Cash + STI yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of -2.80%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
-5.88%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
2.67%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
2.51%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
0.42%
Current assets growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.06%. Joel Greenblatt sees a potential liquidity edge if well allocated.
5.47%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 1.30%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
-8.80%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-8.80%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-0.01%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
0.01%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
-0.01%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
4.24%
≥ 1.5x the Medical - Pharmaceuticals median of 1.15%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
-33.33%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
2.78%
≥ 1.5x the Medical - Pharmaceuticals median of 0.78%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
8.07%
Payables growth above 1.5x Medical - Pharmaceuticals median of 3.24%. Jim Chanos might see a warning sign of stressed supplier payments.
-13.93%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-36.44%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-36.08%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-13.27%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
2.18%
50-75% Medical - Pharmaceuticals median of 2.95%. Mohnish Pabrai notes fewer yoy liability expansions.
-13.21%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.43%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
1.07%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
2.08%
Above 1.5x Medical - Pharmaceuticals median of 0.60%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
4.63%
Below half Medical - Pharmaceuticals median of -0.94%. Jim Chanos suspects poor profitability or large dividend drains.
-11.11%
AOCI growth below half of Medical - Pharmaceuticals median 0.75%. Joel Greenblatt sees fewer exposures vs. peers.
No Data
No Data available this quarter, please select a different quarter.
3.84%
≥ 1.5x Medical - Pharmaceuticals median of 1.45%. Joel Greenblatt sees stronger equity growth vs. peers.
2.78%
≥ 1.5x Medical - Pharmaceuticals median of 1.19%. Joel Greenblatt sees more aggressive expansions than peers.
-0.01%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-13.52%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
2.47%
Above 1.5x Medical - Pharmaceuticals median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.